Hvivo, the company that owns the Queen Mary BioEnterprises Innovation Centre, a laboratory in the east of London, published a vacancy in which they were looking for 24 subjects who want to be infected, voluntarily, with two strains of the coronavirus, 229E and OC43, which are thought to cause, among other a things, very mild respiratory symptoms.

However, a vaccine that can combat these smaller symptoms, could possibly also take on the Covid-19 variant.

Volunteers will receive £3,500 (just over €4,000) for their participation and can find more information on Hvivo’s trial on their website, aptly named ‘FluCamp‘.

The subjects will be quarantined for two weeks, and their diet will be restricted during the testing. They will be monitored by doctors, have to take medication and will be tested.

READ ALSO:

Coronavirus: Iran Reports 49 New Coronavirus Deaths, Highest Single-day Toll

Cathal Friel, the executive chairman of Hvivo’s parent company, Open Orphan, said it placed the company at the “forefront of the fight against the outbreak,” according to local media.

World Health Organisation (WHO) has described the growing rate of the crisis as a 'sober moment' as virus plunged the world into unrest.

Since its outbreak in China, Italy has by far recorded the largest number of case of the epidemic in Europe with confirmed cases shockingly soaring up from 5,883 to 7,375 on Saturday.

Tragically, the number of death casualties from coronavirus in Italy have towered up from 233 to 366, though the Protection Agency said 622 fully recovered from the virus Sunday, March 8.

brusselstimes.com